| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD1 |
| Uniprot No | Q15116 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-167aa |
| 氨基酸序列 | LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSN QTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCG AISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDCD1重组蛋白的参考文献示例(内容为虚构，仅供格式参考)：
1. **《Structural and Functional Analysis of Recombinant PDCD1 Protein》**
- 作者：Smith A, et al.
- 摘要：本研究通过大肠杆菌表达系统成功制备了PDCD1重组蛋白，并利用X射线晶体学解析其三维结构。研究揭示了PDCD1与其配体PD-L1结合的关键表位，为设计新型免疫检查点抑制剂提供了结构基础。
2. **《Recombinant PDCD1 Protein Enhances T-cell Activation in vitro》**
- 作者：Chen L, et al.
- 摘要：通过哺乳动物细胞表达系统获得高纯度PDCD1重组蛋白，实验表明该蛋白能竞争性阻断PD-1/PD-L1通路，显著恢复耗竭T细胞的活性，提示其在肿瘤免疫治疗中的应用潜力。
3. **《Optimization of PDCD1 Recombinant Protein Production in Yeast Expression Systems》**
- 作者：Wang Y, et al.
- 摘要：研究比较了毕赤酵母和酿酒酵母系统中PDCD1重组蛋白的表达效率，通过密码子优化和发酵条件调控将蛋白产量提高3倍，为大规模制备提供了可行方案。
4. **《PDCD1 Recombinant Protein as a Biomarker for Autoimmune Disease Diagnosis》**
- 作者：Kim H, et al.
- 摘要：开发基于PDCD1重组蛋白的ELISA检测方法，发现类风湿性关节炎患者血清中PD-1水平异常升高，提示其可能作为自身免疫疾病的诊断标志物。
PDCD1 (Programmed Cell Death Protein 1), also known as PD-1. is a transmembrane protein belonging to the immunoglobulin superfamily. It functions as a critical immune checkpoint receptor expressed primarily on activated T cells, B cells, and myeloid cells. PD-1 interacts with its ligands PD-L1 and PD-L2. which are often overexpressed in tumor cells or infected tissues. This interaction suppresses T-cell activation, proliferation, and cytokine production, thereby maintaining immune tolerance and preventing autoimmunity. However, in pathological contexts like cancer, the PD-1/PD-L1 axis is exploited by tumors to evade immune surveillance.
Recombinant PDCD1 protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble, functional forms of the extracellular domain for research and therapeutic applications. It retains ligand-binding capacity, enabling studies on PD-1/PD-L1 interactions, immune modulation mechanisms, and inhibitor screening. In drug development, recombinant PDCD1 serves as a tool to validate monoclonal antibodies (e.g., pembrolizumab, nivolumab) that block this pathway, revitalizing antitumor immunity. Additionally, it aids in structural biology (e.g., crystallography) to map binding epitopes and optimize therapeutic agents.
The clinical success of PD-1-targeted checkpoint inhibitors has revolutionized oncology, highlighting the importance of recombinant PDCD1 in advancing immunotherapy. Its applications extend to autoimmune disease research, where dysregulated PD-1 signaling contributes to pathogenesis. By providing a controlled, scalable source of PD-1 protein, recombinant technology accelerates both mechanistic studies and biotherapeutic innovation.
×
